You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 24, 2024

Investigational Drug Information for Epacadostat


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Epacadostat?

Epacadostat is an investigational drug.

There have been 56 clinical trials for Epacadostat. The most recent clinical trial was a Phase 3 trial, which was initiated on December 7th 2017.

The most common disease conditions in clinical trials are Carcinoma, Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Incyte Corporation, Merck Sharp & Dohme Corp., and National Cancer Institute (NCI).

There are sixty-four US patents protecting this investigational drug and one international patents.

Recent Clinical Trials for Epacadostat
TitleSponsorPhase
An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial CarcinomaIncyte CorporationPhase 2
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.European Network for Gynaecological Oncological Trial groups(ENGOT)Phase 2
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.GOG FoundationPhase 2

See all Epacadostat clinical trials

Clinical Trial Summary for Epacadostat

Top disease conditions for Epacadostat
Top clinical trial sponsors for Epacadostat

See all Epacadostat clinical trials

US Patents for Epacadostat

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Epacadostat ⤷  Sign Up Synergistic combination of immunologic inhibitors for the treatment of cancer The University of Chicago (Chicago, IL) ⤷  Sign Up
Epacadostat ⤷  Sign Up Tank-binding kinase inhibitor compounds Gilead Sciences, Inc. (Foster City, CA) ⤷  Sign Up
Epacadostat ⤷  Sign Up Heterocyclic compounds as PI3K-.gamma. inhibitors Incyte Corporation (Wilmington, DE) ⤷  Sign Up
Epacadostat ⤷  Sign Up Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Epacadostat

Drugname Country Document Number Estimated Expiration Related US Patent
Epacadostat Argentina AR072490 2028-07-08 ⤷  Sign Up
Epacadostat Australia AU2009268739 2028-07-08 ⤷  Sign Up
Epacadostat Australia AU2014210662 2028-07-08 ⤷  Sign Up
Epacadostat Australia AU2016204914 2028-07-08 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.